Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Over the last 7 days, the United States market has remained flat, yet it is up 5.7% over the past year with earnings forecasted to grow by 13% annually. In this context of steady growth, identifying ...

Part of Ottery – The water supply to a part of Ottery will be shut off temporarily from 8:00 until 18:00 on Tuesday, 22 April ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...